Spyre Therapeutics Inc.
The Network Fund basket is what these analysts build together, and what the Network Fund will hold as a token.
Follow Reserve on X
Value Investing Edge@StonkValueBiotech sectors is a trillion-dollar market opportunity. Best biotech stocks to won 2026 and beyond: ONCOLOGY $ERAS — Erasca, Inc. $IBRX — ImmunityBio, Inc. $TNGX — Tango Therapeutics, Inc. $RVMD — Revolution Medicines, Inc. $CGON — CG Oncology, Inc. $URGN — UroGen Pharma Ltd.
Jonathan Faison@jfais20Mid-week Chat conversations: Stunning data for $MRK's tulisokibart in hidradenitis suppurativa (whole new market opened up for TL1A) Good for peers like $SYRE $XNCR with "me-betters", bearish for other contenders like $MLTX $IOVA multi-bagger for a few ppl, NSCLC update soon
A.A@a_a_freeThis is what one of the best BD in IBD and immunology said about the space. That's why $SYRE and $ORKA are expensive and probably at least one of them will be taken by 2027 if not both. When you see the number of companies who recently went IPO, private companies and the recent
@bioinvestor24 $ABBV CEO and mgt just confirmed their focus in IBD and immunology on combinations and extended half life and as being the next frontier $SYRE CEO affirms his assets are in a different tier vs Abbv .. co formulation volumes , extended half life and exposure.A.A@a_a_freeThis is what one of the best BD in IBD and immunology. That's why $SYRE and $ORKA are expensive and probably at least one of them will be taken by 2027 if not both. When you see the number of companies who recently went IPO, private companies and the recent deals to start
@bioinvestor24 $ABBV CEO and mgt just confirmed their focus in IBD and immunology on combinations and extended half life and as being the next frontier $SYRE CEO affirms his assets are in a different tier vs Abbv .. co formulation volumes , extended half life and exposure.
